Zacks Investment Research downgraded AngioDynamics, Inc. (NASDAQ:ANGO) to Hold in a statement released earlier today.
- Updated: January 11, 2017
Zacks Investment Research has downgraded AngioDynamics, Inc. (NASDAQ:ANGO) to Hold in a report released on Wednesday January 11, 2017.
Previously on 01/10/2017, Zacks Investment Research released a statement about AngioDynamics, Inc. (NASDAQ:ANGO) increased the target price from $0.00 to $19.00. At the time, this indicated a possible upside of 0.09%.
Just yesterday AngioDynamics, Inc. (NASDAQ:ANGO) traded -1.60% lower at $17.37. AngioDynamics, Inc.’s 50-day moving average is $16.77 and its 200-day moving average is $16.30. The last stock price is up 5.33% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.04% over the same time period. 261,524 shares of ANGO traded hands, down from an average trading volume of 349,597
Recent Performance Chart
AngioDynamics, Inc. has with a one year low of $9.71 and a one year high of $17.64 and has a total market value of $0.
A total of 4 analysts have released a research note on ANGO. One analyst rating the company a strong buy, two analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $14.63.
More About AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.